Oncología de Son Espases y Son Llàtzer participan en el 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Javier Martín Broto y José Durán Moreno, oncólogos del Hospital Universitario Son Espases, participaron con la comunicación en formato póster titulada: "Prognostic impact of COL5A2 and ACVR1B genes in intestinal high risk localized GIST. A Spanish Group for Research on Sarcoma (GEIS) study".

Javier Martín Broto, oncólogo del Hospital Universitario Son Espases, participó con la comunicación en formato póster titulada: "CUL4A and ERCC1 genesas predictive factors for trabectedin efficacy in advanced soft tissue sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) study".

Isabel Garau, oncóloga del Hospital Son Llàtzer, y Antònia Perelló, oncóloga del Hospital Universitario Son Espases, participaron con la comunicación en formato póster titulada: "Time to definitive deterioration in patients with metastatic breast cancer subjected to second-line monochemotherapy.Time to definitive deterioration in patients with metastatic breast cancer subjected to second-line monochemotherapy".

Aranzazu Gonzalez del Alba, oncóloga del Hospital Universitario Son Espases, participó con las comunicaciones en formato póster tituladas:

• Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).
• Phase II study of pazopanib plus interferon alfa as first-line therapy of advanced renal cell carcinoma: a Spanish Oncology Genitourinary Group (SOGUG) study.
• Chemotherapy treatment patterns and survival outcomes in patients with visceral metastatic upper tract urothelial cell carcinoma.
• Randomized, placebo-controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)—SOGUG 2011-02.
• Novel agents’ sequencing following first-line docetaxel in mCRPC patients: CAPRO study.

Pablo Luna Fra, oncólogo del Hospital Universitario Son Espases, participó con la comunicación en formato póster titulada: "Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study—NCT01692496".

Isabel Bover, oncóloga del Hospital Son Llàtzer, participó con la comunicación en formato póster titulada: "Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study. Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study".

Esther Falco, oncóloga del Hospital Son Llàtzer, participó con la comunicación en formato póster titulada: "Regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD)".

Aitor Azkarate, oncólogo del Hospital Universitario Son Espases, participó con la comunicación en formato póster titulada: "Prognostic factors for survival in patients with advanced gastric cancer treated with chemotherapy".

Hermini Manzano, oncólogo del Hospital Universitario Son Espases, participó con la comunicación en formato póster titulada: "Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)]".

[Fuente: Bibliosalut]

[Foto: ASCO]